Cencora (NYSE:COR) Issues FY 2026 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 17.650-17.900 for the period, compared to the consensus EPS estimate of 17.600. The company issued revenue guidance of $334.2 billion-$340.6 billion, compared to the consensus revenue estimate of $345.9 billion.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Barclays upped their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. William Blair began coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. JPMorgan Chase & Co. upped their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Wells Fargo & Company increased their price target on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Finally, Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $391.58.

Cencora Trading Up 1.1%

Cencora stock traded up $2.84 during midday trading on Thursday, reaching $255.58. 1,580,098 shares of the stock traded hands, compared to its average volume of 1,418,660. The company has a 50-day simple moving average of $330.01 and a two-hundred day simple moving average of $342.75. Cencora has a 12-month low of $244.82 and a 12-month high of $377.54. The firm has a market cap of $49.72 billion, a PE ratio of 30.69, a price-to-earnings-growth ratio of 1.43 and a beta of 0.64. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the business earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts expect that Cencora will post 17.58 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

Key Stories Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Management raised FY2026 adjusted EPS guidance to $17.65–$17.90 and authorized a $1 billion share repurchase program, signaling confidence in profitability and capital returns. Read More.
• Positive Sentiment: Cencora declared a quarterly dividend ($0.60/share), supporting yield-seeking investors and returning cash to shareholders. Read More.
• Neutral Sentiment: Adjusted EPS rose year‑over‑year to $4.75 but missed the Street by roughly $0.07; management hosted an earnings call with mixed messages — margin gains in certain areas but softer revenue trends overall. Read More.
• Negative Sentiment: Revenue materially missed estimates ($~78.4B reported vs. ~81B consensus) and Cencora cut its revenue growth outlook, highlighting demand and mix pressure in its U.S. Healthcare Solutions business. That top‑line miss is the primary driver of the stock weakness. Read More.
• Negative Sentiment: Management cited specific headwinds: branded‑drug price cuts, lower sales to a large mail‑order client and prior customer losses in the U.S. segment — factors that raise near‑term visibility risk for revenue and cash flow. Read More.
• Negative Sentiment: Some analysts adjusted targets after the print — Robert W. Baird lowered its price target from $420 to $339 (still “outperform”), reflecting reduced revenue visibility despite confidence in execution. Analyst trimming added to selling pressure. Read More.
• Positive Sentiment: Offsetting items: gross‑margin expansion (partly driven by the OneOncology integration) and stronger international operating income were highlighted as execution wins that support longer‑term profitability. Read More.

Institutional Investors Weigh In On Cencora

A number of hedge funds have recently bought and sold shares of the stock. Beacon Pointe Advisors LLC raised its position in shares of Cencora by 1.1% during the 4th quarter. Beacon Pointe Advisors LLC now owns 3,492 shares of the company’s stock worth $1,180,000 after acquiring an additional 37 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of Cencora by 2.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,784 shares of the company’s stock worth $603,000 after acquiring an additional 38 shares in the last quarter. Sumitomo Life Insurance Co. raised its position in shares of Cencora by 0.9% during the 4th quarter. Sumitomo Life Insurance Co. now owns 4,462 shares of the company’s stock worth $1,507,000 after acquiring an additional 39 shares in the last quarter. Evergreen Capital Management LLC raised its position in shares of Cencora by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 1,233 shares of the company’s stock worth $370,000 after acquiring an additional 45 shares in the last quarter. Finally, Mission Creek Capital Partners Inc. raised its position in shares of Cencora by 5.1% during the 4th quarter. Mission Creek Capital Partners Inc. now owns 1,158 shares of the company’s stock worth $391,000 after acquiring an additional 56 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.